Compare Rush Street Interactive Inc (RSI) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rush Street Interactive Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Rush Street Interactive Inc trades at $18.31 (market cap $2.20B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 2.2× Rush Street Interactive Inc's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Rush Street Interactive Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rush Street Interactive Inc for 13 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| RSI | TVTX | |
|---|---|---|
Market Cap | $2.20B | $4.88B |
Volume | 4,146,093 | 1,668,577 |
Sector | Consumer Cyclical | Health |
52-Week High | $34.52 | $67.52 |
52-Week Low | $15.89 | $26.79 |
Typical Hold Time | 13 Days | 0 Days |
Enterprise Value | $1.87B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RSI trades at $19.07, up 1.92% with bearish technical signals but strong analyst support. The company shows revenue growth to $1.13B in 2025 with improving cash flow, though net margins remain thin at 2.33%. Recent Q2 2026 earnings beat expectations at $0.15 EPS, while institutional interest grows with BlackRock's $448M investment in August 2026.
Outlook remains positive with 77% analyst buy ratings and $33.75 price target offering 77% upside. Key risks include competitive pressures in online gaming and margin compression. The stock presents growth potential but requires monitoring of profitability trends and market sentiment shifts.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
